Genentech, Inc. v. Zydus Lifesciences Global FZE, No. 2:26-cv-14713 (D.N.J.), is a complaint for patent infringement filed November 13, 2026, by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. The complaint demands a jury trial under Federal Rule of Civil Procedure 38. The complaint says Genentech is a Delaware corporation with its principal place of business in South San Francisco, California, and that it holds the exclusive right to sell, distribute, and market EVRYSDI tablets in the United States. It says Hoffmann-La Roche Inc. is a New Jersey corporation with its principal place of business in Little Falls, New Jersey, and that Roche helped develop and obtained FDA approval to market EVRYSDI. It says PTC Therapeutics, Inc. is a Delaware corporation with its principal place of business in Warren, New Jersey.
On information and belief, the complaint alleges that Zydus Lifesciences Global FZE is organized under the laws of Dubai, United Arab Emirates, with its principal place of business in Dubai, and is a wholly owned subsidiary of, and controlled by, Zydus Lifesciences Ltd.; that Zydus Lifesciences Ltd. is organized under the laws of India, with its principal place of business in Ahmedabad, Gujarat, India; and that Zydus Pharmaceuticals (USA) Inc. is organized under the laws of New Jersey, with its principal place of business in Pennington, New Jersey, and is a wholly owned subsidiary of, and controlled by, Zydus Lifesciences Ltd. It alleges, on information and belief, that the three Zydus defendants acted collaboratively and in concert to prepare and file ANDA No. 222036.
The complaint invokes subject-matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202. It alleges that venue is proper under 28 U.S.C. §§ 1391(b), 1391(c), and 1400(b). As to Zydus Pharmaceuticals (USA) Inc., it alleges that the company resides in New Jersey by being incorporated there, maintains a regular and established place of business in Pennington, New Jersey, and participated in submitting the tablets ANDA in New Jersey. As to the foreign defendants, it alleges that they may be sued in any judicial district in which they are subject to personal jurisdiction, and it pleads personal jurisdiction over them under Federal Rule of Civil Procedure 4(k)(2), among other grounds.
The drug and the ANDA
The complaint says Genentech holds New Drug Application No. 219285 for EVRYSDI (risdiplam) tablets, which it describes as a survival of motor neuron 2 splicing modifier indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. It says the active ingredient is risdiplam, that each tablet contains 5 mg of risdiplam, and that the tablets are indicated for patients who are 2 years of age and older weighing 20 kg or more. According to the complaint, EVRYSDI was initially approved in August 2020 as a powder for oral solution, and the tablets were approved in February 2025.
On information and belief, the complaint alleges that the Zydus defendants filed ANDA No. 222036 under section 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j), seeking approval to manufacture, use, sell, and/or market a generic version of EVRYSDI tablets, and that the ANDA refers to and relies upon the EVRYSDI NDA and contains data that, according to Zydus, demonstrates bioequivalence. It alleges, on information and belief, that Zydus included a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that, in Zydus's opinion, the asserted patents are invalid, unenforceable, and/or that certain claims will not be infringed by the ANDA product. It also alleges, on information and belief, that Zydus did not include a Paragraph IV certification as to U.S. Patent 9,586,955, which is not an asserted patent, and instead included a Paragraph III certification under 21 U.S.C. § 355(j)(2)(A)(vii)(III) that Zydus will not market the ANDA product until after that patent expires.
The complaint says the plaintiffs received written notice of the tablets ANDA by a letter dated October 2, 2026, together with a detailed statement of Zydus's alleged bases for invalidity, unenforceability, and/or noninfringement of the asserted patents, and that this action was commenced within 45 days of receipt of that letter. It alleges that the notice letter and detailed statement do not contain any factual or legal allegations that the '955 patent is invalid, unenforceable, or will not be infringed, and that the detailed statement does not provide any factual bases for stating that the asserted patents are unenforceable.
The complaint alleges that the five asserted patents, as well as the '955 patent, are listed in FDA's Orange Book in connection with EVRYSDI tablets and the related NDA, and that the asserted patents are also listed in connection with EVRYSDI for oral solution and NDA No. 213535. It further alleges, on information and belief, that the Zydus defendants filed ANDA No. 219902 seeking approval of a generic version of EVRYSDI for oral solution, with Paragraph IV certifications as to the '444, '789, and '273 patents. It says Zydus did not include a Paragraph IV certification in that powder ANDA for the '754 and '646 patents, and it says the plaintiffs received written notice of the powder ANDA by letters dated October 21, 2024, January 14, 2025, and December 15, 2025.
The patents
The complaint asserts five patents. It alleges that Roche and PTC jointly own U.S. Patent 9,969,754, titled Compounds for Treating Spinal Muscular Atrophy, which issued on May 15, 2018, and U.S. Patent 11,827,646, of the same title, which issued on November 28, 2023, and that Roche has licensed its rights under those patents to Genentech. It alleges that Roche owns U.S. Patent 11,534,444, titled Treatment of SMA, which issued on December 27, 2022; U.S. Patent 12,122,789, titled Forms of Pyrido[1,2-a]pyrimidin-4-one Derivatives, Its Formulation and Its Process of Making, which issued on October 22, 2024; and U.S. Patent 12,350,273, also titled Treatment of SMA, which issued on July 8, 2025, and that Roche has licensed its rights under those three patents to Genentech.
The complaint recites claim 36 of the '754 patent as a compound of claim 24, wherein the compound is 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, and says that at least claim 36 encompasses risdiplam. It recites claim 1 of the '646 patent as a method for the treatment of spinal muscular atrophy in a human in need thereof comprising administering a therapeutically effective amount of a depicted compound, or a pharmaceutically acceptable salt thereof, and recites claim 11 as another such method. It says that at least claims 1 and 11 of the '646 patent encompass treating SMA with a therapeutically effective amount of risdiplam.
It recites claim 1 of the '444 patent as a method of treating SMA comprising administering 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof, at a dose of 0.25 mg/kg for a subject with a body weight of less than 20 kg and 5 mg for a subject with a body weight of more than or equal to 20 kg, and recites claim 9, which depends from claim 1, as that compound or salt administered orally at a dose of 5 mg for a subject weighing 20 kg or more. It recites claim 1 of the '789 patent as a solid form of a compound of formula (I) that is crystalline Form A having an x-ray powder diffraction pattern comprising at least two peaks selected from 8.3, 11.4, 15.1, 15.9, 17.0, 24.0, and 25.6 degrees two-theta, each plus or minus 0.2, and recites claim 9 as a pharmaceutical composition comprising that solid form and a pharmaceutically acceptable excipient. It recites claim 1 of the '273 patent as a method of treating SMA in a human patient comprising administering a pharmaceutical composition comprising a compound of formula (I) at a once-daily oral dose of 5 mg, where the patient has a body weight of more than or equal to 20 kg.
The counts and the prayer
Counts I and II are brought by all three plaintiffs; Counts III, IV, and V are brought by Genentech and Roche. Count I alleges infringement of at least claim 36 of the '754 patent under 35 U.S.C. § 271(e)(2)(A) by submission of the tablets ANDA with a Paragraph IV certification. The complaint says that, in the October 2, 2026 notice letter, Zydus has not contested infringement of claims 1 to 8, 10 to 11, 21 to 24, 27 to 28, 31, and 36 of the '754 patent. Count II alleges infringement of at least claims 1 and 11 of the '646 patent under § 271(e)(2)(A), and says Zydus has not contested infringement of claims 1 and 11, or any claim, of that patent. Count III alleges infringement of at least claim 9 of the '444 patent under § 271(e)(2)(A), and says Zydus has not contested infringement of claims 1 to 18 and 20 to 35 of that patent. Count IV alleges infringement of at least claims 1 and 9 of the '789 patent under § 271(e)(2)(A), and says Zydus has not contested infringement of claims 1 to 9 and 12 to 31 of that patent. Count V alleges infringement of at least claim 1 of the '273 patent under § 271(e)(2)(A), and says Zydus has not contested infringement of claim 1, or any claim, of that patent.
On information and belief, the complaint alleges that the tablets ANDA essentially copies the EVRYSDI label as required by FDA, see 21 C.F.R. § 314.94(a)(8)(iv), and therefore instructs, recommends, encourages, and/or suggests that physicians and/or patients infringe the asserted method claims of the '646, '444, and '273 patents, and that the ANDA product is not a staple article of commerce and has no substantial uses that do not infringe those claims. Each count also alleges that commercial manufacture, use, offer for sale, sale, or importation of the ANDA product before the relevant patent expires would directly infringe, or contribute to or induce infringement of, the asserted claims under 35 U.S.C. § 271, literally or under the doctrine of equivalents; that the plaintiffs are entitled to relief under 35 U.S.C. § 271(e)(4), including an order that FDA set the effective date of approval no earlier than the patent expires; that Zydus was aware of the patent when it submitted the ANDA; and, on information and belief, that Zydus's statement of the factual and legal basis regarding invalidity is devoid of a good faith basis in either the facts or the law.
The prayer seeks judgments of infringement of each asserted patent under § 271(e)(2)(A), and judgments that Zydus will infringe under § 271 if it markets the ANDA product before those patents expire; an order under § 271(e)(4)(A) that the effective date of any approval of ANDA No. 222036 shall not be earlier than the expiration of the five asserted patents, including any extensions, adjustments, or exclusivities; an order that Zydus amend its Paragraph IV certification to a Paragraph III certification as provided in 21 C.F.R. § 314.94(a)(12)(viii)(A); preliminary and permanent injunctions under 35 U.S.C. §§ 271(e)(4)(B) and 283; monetary relief under §§ 271(e)(4)(C) and 284, with interest, if the ANDA product is commercially made, used, offered, sold, or imported before expiration; attorneys' fees under 35 U.S.C. § 285; costs and expenses; and other relief the court deems just and proper.
The earlier risdiplam suits
This is not the first EVRYSDI suit against the Zydus companies. Genentech, Hoffmann-La Roche Inc., and PTC sued them, together with another generic company, on November 18, 2024, No. 2:24-cv-10567 (D.N.J.), over ANDA No. 219902 and the other company's ANDA. That complaint asserted the '444 patent and U.S. Patent 11,938,136 against the Zydus companies, and the '955, '754, '444, '646, and '136 patents against the other company. Genentech and Hoffmann-La Roche Inc. sued the Zydus companies on the '789 patent on February 27, 2025, No. 2:25-cv-01521, and sued them and another generic company on the '273 patent on October 31, 2025, No. 2:25-cv-17100. The court has consolidated those cases, with a fourth case on the '789 patent against another generic company, No. 2:24-cv-11308, under No. 2:24-cv-10567 for all pretrial purposes, and it construed "crystalline Form A" in the '789 patent in an October 23, 2026 opinion. Genentech, Hoffmann-La Roche Inc., and PTC also asserted all five patents asserted here, with the '955 patent, against other generic companies over a proposed generic of EVRYSDI tablets on June 4, 2026, No. 2:26-cv-06555 (D.N.J.).
What to watch next
Watch for the Zydus defendants' answer, counterclaims, or a Rule 12 motion, and for any motion to consolidate or coordinate this case with Consol. No. 2:24-cv-10567. The case can end at any time, including by settlement or voluntary dismissal.